Genmab A/S (GMAB) Stock Analysis & Winston Score

Genmab is a Danish biotechnology company that creates antibody-based medicines to treat cancer and other serious diseases. Its most important products include Darzalex (daratumumab), used to treat multiple myeloma, and Kesimpta, used for multiple sclerosis — both developed with its partner Johnson & Johnson. Genmab is one of the leading antibody technology companies in the world and licenses its proprietary platforms to large pharmaceutical partners. Genmab makes money primarily through royalties and milestone payments from its pharmaceutical partners, rather than selling drugs directly to patients itself. It operates mainly out of Denmark and the Netherlands, with a growing presence in the United States and Japan. Its competitive edge comes from its proprietary antibody technologies, including DuoBody, which allows it to build unique partnerships with larger drugmakers. The key risk is that Genmab depends heavily on a small number of partner-driven products, particularly Darzalex, meaning any slowdown in that drug's sales could significantly hurt revenue.